Influenza virus infections are a leading cause of morbidity and mortality worldwide. This is due in part to the continual emergence of new viral variants and to synergistic interactions with other viruses and bacteria. There is a lack of understanding about how host responses work to control the infection and how other pathogens capitalize on the altered immune state. The complexity of multi-pathogen infections makes dissecting contributing mechanisms, which may be non-linear and occur on different time scales, challenging. Fortunately, mathematical models have been able to uncover infection control mechanisms, establish regulatory feedbacks, connect mechanisms across time scales, and determine the processes that dictate different disease
| INTRODUC TI ON
Influenza viruses are important respiratory pathogens that infect 15-65 million individuals each year in the United States with over 200 000 of these infections resulting in hospitalizations. 1, 2 Despite available vaccines and antiviral therapies, influenza viruses remain a public health threat because they continue to evolve and novel strains emerge from zoonotic sources several times a century to cause pandemics. In addition, other viral or bacterial pathogens can invade and exacerbate influenza disease severity. Two or more pathogens can interact in ways that are not intuitive with numerous alterations occurring on varying time scales. Furthermore, different viral and/or bacterial strains, initial doses, timings of the secondary insult, and host immune status can result in distinct infection kinetics and disease outcomes. [3] [4] [5] [6] [7] [8] [9] [10] [11] Examining every scenario and detailing different regulatory mechanisms is challenging even with animal models that can recapitulate many aspects of clinical diseases. This has limited our global understanding of influenza-related diseases and emphasized a need for quantitative analyses that can detail the biology and evaluate different mechanisms simultaneously and rigorously.
During the past decade, mathematical models that describe host-pathogen and pathogen-pathogen interplay during influenza DOI: 10.1111/imr.12692
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have made it possible to dissect critical mechanisms that drive the infection. The models have successfully quantified and predicted the viral load kinetics from clinical and experimental infections, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] the symptoms that arise during infection, 12,13 the dynamics and efficiency of different host immune responses, 14, 17, 18, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] the effect of different viral and host factors, 15, 16, [20] [21] [22] 35 the efficacy and design of vaccines and antiviral therapies, 14, [19] [20] [21] [22] [36] [37] [38] [39] [40] and the mechanisms of coinfection between influenza viruses and other viruses or bacteria. [41] [42] [43] [44] [45] Remarkably, influenza viral load dynamics can be described using as few as 3-4 equations for populations of uninfected cells, infected cells, and virus. 14 The kinetics of host immune responses and/or coinfection with other pathogens can be accurately described by adding only 1-2 more equations. 41 Simple models like these are optimal because they readily allow for mathematical and statistical analyses that extract information about the underlying biology. Although models are typically first calibrated to data to ensure a robust recapitulation of the infection kinetics and to estimate the rates of growth and decay, this is not the only goal. The underlying model structure (eg, non-linear feedbacks between different cell populations), the behavior of the resulting parameter estimates (eg, when two parameters are correlated), and in silico experiments that predict the response under perturbation (eg, with antivirals) can all reveal hidden regulatory mechanisms that may not be readily apparent from the data itself and/or cannot be tested in the clinic or laboratory. A schematic of this model-experiment exchange is shown in Figure 1 .
Improvements in the availability of quantitative data in recent years has led to more robust models being developed and to the predictions of some of these models being validated in the laboratory.
One collection of studies, which are described here, illuminate the accuracy and predictive capability of mathematical models and the importance of designing confirmatory experiments to define new biology and improve the models. Here, I review current approaches in modeling influenza virus kinetics and host-pathogen interplay, recent advances in modeling viral-bacterial and viral-viral coinfections, the techniques used to identify controlling mechanisms, biological interpretations of the model results, and the benefits of model-driven experimental design.
| MODELING INFLUENZ A VIRUS INFEC TI ON S: THE G OLD S TANDARD
Influenza A viruses infect the upper and lower respiratory tracts to cause acute, self-limiting infections. The dynamics of the infection are rapid with the virus establishing quickly and replicating exponentially to high titers within 1-2 days. In the majority of cases, the infection resolves within 7-10 days, but viral loads can remain elevated in children and immunocompromised individuals.
The mechanisms that drive these kinetics and how they might be altered by therapy or other pathogens are not well understood even though many of the contributory cytokines, chemokines, and cells are known.
Mathematical models have accurately described viral load kinetics without including equations for specific host responses. [46] [47] [48] The models assume that susceptible epithelial cells ("target cells") are limited and that virus declines once the majority of cells are infected. 14 Accurate predictions have been made under this assumption, which does not specify the mechanisms by which target cells are limited. 
| Viral kinetic model
The majority of influenza virus infection models developed thus far have utilized a common model core, that is, the standard viral kinetic model 14 
| Model interpretation and the accuracy of the target cell limited hypothesis
A central assumption of the viral kinetic model (Figure 2 ) is that the number of target cells is limited. 14 25 Simply reducing the number of initial target cells (T 0 ) was insufficient to replicate the dose-dependent dynamics. 25 This may indicate a deficiency in the model or that some host responses are more functional with low dose infection, which has been proposed in other studies using low doses. 41 
| Quantifying the rates of infection and the response to perturbation
Understanding time-dependent mechanisms that control viral infection dynamics requires that mathematical models be calibrated to experimental or clinical data and thoroughly analyzed. Fitting a model to data ensures that the equations accurately describe the infection dynamics and provides estimates of the rates of infection, production, and clearance. It also begins to reveal the relationship between these rates and the strength needed to induce a change in the dynamics (eg, with drug therapy or coinfection). Further F I G U R E 1 Data-Driven Mathematical Modeling and Model-Driven Experimental Design. Data-driven mathematical modeling studies are iterative and entail developing a model to describe the underlying biology, calibrating the model to experimental or clinical data, analyzing the model with mathematical techniques, using the model to make predictions and design experiments, and validating the predictions in the laboratory or clinic investigating how changing the rates affects outcome, for example, through sensitivity analysis, has generated predictions about the response to therapy 14, [19] [20] [21] 36, 56 or coinfection with other pathogens. [41] [42] [43] 45 Collectively, these types of analyses reveal aspects of influenza biology that are not immediately available from the experimental or clinical data alone. 24 Monte Carlo Markov Chain (MCMC), 13, 15, 22, 35, 49 Gaussian processes (GP), 53 and maximum likelihood estimation (MLE). 16, 26, 41 Until recently, it was relatively well accepted that the choice of estimation scheme is not critical. However, contrasting parameter estimates may result and some evidence suggests that ASA or GP methods can outperform MCMC and MLE methods in terms of accuracy, convergence, and run time. 24, 53 Further investigation is needed to ensure robust results, particularly because MCMC methods are popular.
Uniquely identifying each parameter in a model has been challenging 57,58 but has not limited the predictive capability. 41, 44 The standard viral kinetic model has seven unknown parameters (β, p, k, c, δ, V 0 , and T 0 (see Figure 2) ). In most studies, the values of the eclipse phase parameter (k) and initial target cells (T 0 ) are fixed because their values can be calculated. 14 However, these can be left free 24, 53 without compromising the predictive capability. One problematic parameter has been the virus clearance rate (c), which often
estimates to large values that may not be biologically relevant. 16, 24 This is because the model attempts to capture the rapid decrease in free virus shortly after the infection is initiated as virus infects cells (~0-4 hours). However, this challenge can be overcome by setting the initial free virus (V 0 ) to zero (ie, V 0 = 0) and assuming that the initial number of infected cells is positive (ie, I 1 > 0). 24 Using this assumption recovers virus clearance rates (c) that are more reliable. 24 Ensuring robust predictions requires more than estimation of the model parameters. A thorough investigation into the uncertainty of the estimates and the corresponding model solution is also required.
This has been particularly true when attempting to determine significant differences in parameter estimates generated by fitting a model to data obtained under varied experimental conditions, such as during 
| Insight from analytical solutions: timedependent mechanisms
The predictive capability of influenza models goes beyond data fitting, parameter estimation, and sensitivity analysis. The simplicity of the model is beneficial because additional mathematical analyses are feasible. 65 It can be easily observed that viral load dynamics split into two log-linear (ie, exponential) phases: growth and decay. During the initial growth period, few target cells are infected and their population remains relatively constant (A.M. Smith, unpublished data). This information was used to obtain an equation that describes exponential virus growth 65 :
is the slope of the viral growth and α 1 is a constant. 23 Prior to virus decay, there is a short, non-linear period (~12 hours)
between virus growth and decay where the growth slows prior to the peak. 65 During the resolution period, most available cells have become infected and there are few target cells remaining (T ≈0).This information was used to obtain an equation that describes exponential virus decay 65 : V 2 (t) = 2 e − t + 3 e −ct + 4 e −kt , where the α i s are constants. This solution is less complex than V 1 (t) and defines the peak and infection resolution. Here, the peak shape is dictated by the rates of eclipse transition (k), virus clearance (c), and infected cell clearance (δ). After the peak, the infected cell death rate (δ) controls the rate of decay (ie, V 2 (t) ≈ V p e − t , where V p is the peak viral load).
Having solutions like these that detail the time-dependent contribution of each infection process to the viral dynamics has been beneficial in establishing robust interpretations of the data and models.
| DE TAILING IMMUNE CONTROL DURING INFLUENZ A VIRUS INFEC TI ON
Throughout influenza virus infection, various immune responses are employed to limit virus spread and maintain integrity of the epithelium ( Figure 2 ). 67 Interferons, including IFN-β (type I), IFN-λ (type III), and to a lesser extent IFN-α (type I), are produced early in the infection. These are most prevalent in the lung from ~2 to 5 days pi and coincide with increases in neutrophils, natural killer (NK) cells, and by including equations for specific immune components. 14, 34 Mechanistic host response models have been built to examine the activation and production of cells or cytokines and the efficacy of different factors (ie, cells or antibodies) in removing virus or infected cells. 15, 18, [27] [28] [29] [30] [31] [32] [33] [34] [35] 49, 50, 72 The models range in complexity with some attempting to incorporate several pro-inflammatory cytokines, anti-inflammatory cytokines, and cell populations. 
| The antiviral type I interferon response
The type I IFN response has potent antiviral activity and is important for control of influenza virus infections. 67 and IFN-α has anti-inflammatory properties. 80, 81 However, influenza viruses can antagonize the IFN response within infected epithelial cells, which is primarily mediated by its non-structural protein, NS1.
82,83
The majority of models developed thus far have focused on the effect of IFN (F) in limiting virus production from infected cells: However, in vitro studies suggest that IFN-induced cell refraction is long-lived, so inclusion of this term may not be supported biologically. 
| VIR AL-VIR AL COINFEC TI ON KINE TI C S
Respiratory viruses like influenza virus, respiratory syncytial virus (RSV), parainfluenza virus (PIV), and rhinovirus (RV) are easily transmitted and have overlapping seasons. Thus, it is not surprising that multiple viruses can be detected within infected individuals.
94-101
The specific outcomes that result from multi-virus infections and Only recently was a mathematical model developed to begin examining respiratory virus coinfections. 42 The model assessed how resource competition between two viruses could alter viral load dy- The model replicated in vitro data from coinfection with IAV and RSV, where IAV inhibits RSV growth, 104 and with IAV and PIV, where PIV enhances IAV growth. 103 A key result was that varied infection kinetics and outcomes could manifest from changing the virus dose or the intrinsic virus growth rate. Although RSV dose may not affect the interaction during IAV-RSV coinfection, 106 the finding is relevant for RV-IAV coinfection. 105 However, interference in the infection of epithelial cells is not the proposed mechanism for these viruses. 105 The model prediction could be interpreted in another way. That is, when the interaction between viruses is competitive, target cells be- 
| INFLUENZ A-BAC TERIA COINFEC TION KINE TIC S
Complications arising from bacterial superinfections have accounted for a significant percentage of influenza-related morbidity and mortality during pandemic influenza (40%-95%) 107 
| Host control of pneumococcal pneumonia
Pneumococci readily colonize the nasopharynx of healthy adults and children [114] [115] [116] and occasionally migrate to other tissues to cause severe disease, such as otitis media, pneumonia, meningitis, and septicemia. 117 Infection with more virulent pneumococcal strains and/or a high dose can also result in pneumonia. 118 For most bacterial infections, a simple model like the ones used for viruses cannot be used. This is because pneumococci are extracellular pathogens and their growth and clearance dynamics are highly dependent on interactions with host immune responses. 60, 64 Indeed, modeling pneumococcal dynamics required equations for several arms of the immune response to accurately capture bacterial kinetics from infections with varied initial doses. 64 Fortunately, many of the important players, including alveolar macrophages (aMΦs), neutrophils, inflammatory MΦ (iMΦ), and pro-inflammatory cytokines, were known. However, the regulatory feedbacks between these populations had not been established. This presents one of the main challenges but also a major benefit to modeling infection kinetics.
The model I developed with coinvestigators described the interplay between pneumococci, aMΦs, neutrophils, iMΦs, cytokine signaling between these populations, and the resulting inflammation/damage caused by bacterial-mediated injury of healthy epithelial cells and by neutrophil infiltration and cytotoxicity. 64 This model mimics infection data from a variety of conditions, including changes in bacterial dose, bacterial strain, murine strain, and under antibacterial therapy. 60, 64, 119 The model accurately predicts that the ratio of aMΦs to bacteria regulates bacterial growth in the early stages of infection and that there is a critical threshold for which a clearance phenotype can be attained. 64 Indeed, this has been observed in several data sets 44, [120] [121] [122] and recently shown for varying combinations of aMΦs and bacteria. 44 The subsequent neutrophil response further dictates bacterial growth kinetics and outcome. 60, 64, 119 Sensitivity of the system revealed that neutrophilmediated damage of the epithelium is an important predictor of outcome. 64 Understanding the role of tissue damage during infections is important and often more closely related to the probability of survival than to pathogen levels. Modeling immune-mediated lung damage has not been attempted for influenza but will undoubtedly prove useful, particularly because tissue damage and defects in tissue repair affect influenza-bacteria related mortality. Following bacterial infection, viral loads rebound and bacterial titers increase to high levels within ~24 hours (Figure 4) . 41 In addition, many host responses are elevated (eg, type I IFNs) while others are dampened (eg, T cells). To investigate the mechanisms that govern these dynamics and begin disentangling the host immune response, the standard viral kinetic model was paired with the aMΦ subset of the pneumococcal model (Figure 4 ). 41 The remaining populations (ie, neutrophils, inflammatory macrophages, cytokines, and damage) in the pneumococcal model were not used because corresponding models that describe the dynamics of these popula- hypotheses and novel hypotheses. The dynamics generated by the model are in good agreement with experimental data and showed that only two alterations were needed to explain the dynamics (Figure 4) . 41 In the model, bacteria increase the rate of virus production from infected epithelial cells (pI 2 ) according to the saturating function â(P) = aP z (Figure 4 ). This term drives the viral rebound.
There was no pre-defined hypothesis or evidence for this increase, but its inclusion in the model was critical. This novel hypothesis subsequently guided several in vitro experimental studies, [125] [126] [127] where at least two potential underlying mechanisms were discovered.
First, S. aureus, another common coinfecting bacteria, was shown to inhibit IFN signaling in influenza-infected cells, which resulted in increased virus production. 125 Although it is unknown if pneumococci have this same ability and to what extent this occurs in vivo, particularly considering the enhanced IFN levels during coinfection, [86] [87] [88] it is an intriguing finding and validates the model-generated hypothesis. Second, pneumococcal neuraminidases, NanA and NanB, have been shown to promote virus replication 126, 128 presumably through cleavage of viral NA. Unsurprisingly, increased viral loads were not observed when the two pathogens were simultaneously administered to cell cultures. 127 This reduced synergism is consistent with in vivo results indicating that the order and timing between pathogens is important.
112
The model also predicted that virus infection decreases the rate of bacterial clearance by aMΦs according to the saturating func-
, where K PV is the half-saturation constant ( Figure 4 ). This term drives bacterial invasion and was initially included to assess previous reports that aMΦs became dysfunctional during influenza. 120 Although the model could not distinguish whether these cells were functionally impaired or were lost during infection, the changes to the aMΦ population were sufficient to drive the bacterial load dynamics. 41 In addition, the resulting parameter estimate indicated that the strength of this reduction was significant (ie, (V) = 85 − 90%). A follow-up experimental study that tracked the aMΦ population with a labeling dye and employed a novel and robust flow cytometry gating strategy better defined the aMΦ dynamics during IAV infection. 113 This study showed a profound depletion of aMΦs over the course of influenza, 113 which may be specific to BALB/cJ mice. 129 In C57BL/6 mice, aMΦs may be functionally inhibited. 129 Fortunately, the model remains accurate because the underlying mechanism is not defined by the model.
Remarkably, the experimental data showed that aMΦs were reduced at 7 days post-influenza by the exact value that the model predicted, that is, 85%-90%. 113 This study effectively validated the model and the estimate of ̂( V). In addition, the data and model together helped identify why bacterial invasion 7 days after influenza results in maximal lethality. 112 How aMΦs become depleted and how their loss alters other host responses and lung function 76, [130] [131] [132] remain open questions.
Parameter estimation played a key role in identifying these mechanisms and in determining that they are independent. 41 The lack of correlation between the parameters involved in the two functions, â(V) and ̂( V), suggested that they described distinct processes.
Unsurprisingly, there were correlations within each function (ie, a is correlated to z, and is correlated to K PV ). 41 Notably, these correlations did not inhibit accurate parameter values from being obtained. 41, 113 These studies illuminate the critical nature of validating a model's predictions to expand its capabilities through correcting any inaccuracies (eg, altering functional forms or adding new equations) and completing new analyses (eg, as in 36, 44 ). It remains unclear if the function describing the increase in virus production (â(P) = aP z ) is accurate. However, the new aMΦ data suggested that the effect on these cells does not saturate (ie,
A more mechanistic model for aMΦ interactions with influenza virus is likely required. Nevertheless, approximating aMΦ depletion ̂( V) through produced robust predictions.
41,44
| The non-linear threshold regulating phenotype and heterogeneity
The new knowledge about aMΦ dynamics and the connection of these data to ̂( V) allowed for another iteration of the modelexperiment exchange. 44 By simulating the model with values for ̂( V) between 0 (0% depletion) and 1 (100% depletion), it was observed that this parameter is a bifurcation parameter that regulates bacterial growth trajectories. 44 Mathematical analyses were used to derive the non-linear threshold that defines the dynamical switch between growth and clearance phenotypes ( Figure 4) . That is, bacteria-aMΦ pairs that fall below the threshold will result in bacterial clearance while pairings above the threshold will lead to bacterial growth. The threshold can be used to identify the dose needed for successful bacterial invasion during influenza. It also suggests that there is a critical point where any dose will initiate the secondary infection (dot on threshold curve in Figure 4 ). This is defined by a relation between the rates of bacterial growth (r) and clearance
. This information was used to design confirmatory experiments, which examined bacterial kinetics for over 20 different combinations of bacteria and aMΦs. 44 The data showed that the threshold was accurate, the rate of bacterial growth/clearance increases with distance above/below the threshold, the phenotype switches if complete clearance is not attained within ~4 hours, and pairings below the threshold result in heterogeneous bacterial titers. 44 This information suggests that the behavior can be predicted for any bacteria-aMΦ pairing, which is ideal. It also aids in the interpretation of bacterial load data and allows for exploration of therapies that manipulate bacterial loads (eg, antibiotics) and aMΦs (eg, immunotherapy or antivirals). 
| Defining the contribution of other mechanisms
In addition to identifying the mechanisms described above, the model also defined the time scales on which they act. For high-dose infection, the slope in the bacterial dynamics changes at ~10 hours postbacterial infection. 41 This indicates that the contribution of aMΦs to clearance is short lived, which has been observed experimentally. 44, [120] [121] [122] However, bacteria grow exponentially after this time, which suggests that neutrophils have little contribution to controlling bacterial kinetics when the dose is sufficiently high. 41 This is consistent with experimental evidence that these cells become dysfunctional throughout influenza. [133] [134] [135] [136] [137] The contribution from neutrophils may be higher during low-dose infection, 41 but this has not been explored in detail. A better understanding of how other cell types and cytokines regulate pathogen kinetics and outcomes of influenzabacterial coinfection should manifest as new models for influenza are developed.
| Connecting mathematically derived mechanisms to omics data
The focus of many infectious disease studies has recently switched from collecting qualitative data to collecting large, quantitative 'omics' data sets that simultaneously measures multiple variables (eg, proteins, metabolic factors, and viral and host transcripts).
Omics studies require computational approaches that assess correlations between different measurements. The computational methods for this type of data are frequently network-based and take into account known interactions (eg, protein-protein) or predicted interactions (ie, correlations) between biological variables.
However, one limitation of this analysis is that it cannot readily assess the dynamic feedback of variables (eg, non-linearities like saturating effects), which often occur on distinct time scales. In contrast, mathematical descriptions of infection processes quantitate the intricate host-pathogen feedbacks and link causation and correlation. Kinetic models determine the time scales of various mechanisms, the rate, magnitude, and effectiveness of immune responses, and whether bifurcating behavior is possible. As more omics data become available, it will be valuable to relate this information to the network analyses because each approach may have related and distinct conclusions. For instance, an omics study that profiled gene expression patterns during influenza-pneumococcal coinfection found that lethality is correlated with an early increase in bacterial replication. 123 Interestingly, the kinetic studies described above made the same conclusion but also identified the regulatory mechanism that governs this behavior. 41, 44 Likewise, the omics study identified a defect in lung repair mechanisms, 123 which the model did not address. Making these types of connections could be significant, particularly because tissue level changes are correlated with disease outcome.
| MODELING THE P OTENTIAL FOR UNIVER SAL VACCINE S
Preventing influenza virus infections through vaccination is ideal.
However, vaccines often lack efficacy because the virus mutates rapidly and novel viruses emerge through recombination. In addition, initiating a robust and long-lasting response to the vaccine is challenging. Even when immunity is generated by a natural infection, long-term protection may not be guaranteed. 138 Furthermore, some evidence from mathematical and experimental studies suggests that viral epitopes may be masked from recognition by B cells, 29, 30 which inhibits the generation of new antibodies during subsequent vaccinations or infections. The model and data were in agreement that the fold increase in antibody titer from baseline declines with repeated vaccination. This was due to an antigen dose threshold that depends on the level of pre-existing antibodies and dictates the level of antibody boosting that can be attained. Sufficiently high antigen doses may be able to reduce the masking of antibodies. 30 However, this could be difficult and may complicate protection by a universal vaccine, which aims to broadly protect against infection with any influenza virus subtype.
| ANTIVIR AL THER APY: THE C A S E FOR IMMUNOMODUL ATORY DRUG S
Without effective vaccines, antivirals remain the primary measure for combatting influenza virus infections. The two major antivirals used to treat influenza are M2 inhibitors (M2Is) and NA inhibitors (NAIs). 66 While M2Is disrupt ion-channel activity of the M2 protein to limit virion uncoating inside the cell, 139, 140 NAIs limit virus spread within the lung by preventing virions from being cleaved from infected cells and infecting new host cells. 139 This reduces symptoms and slows disease progression, but does not significantly reduce the viral burden. 140 Antiviral efficacy is greatest when the drug is administered prophylactically or within the first 24-48 hours of symptom onset. 141 Prophylaxis with NAIs has the most profound effect with a 2.5-3.0 log 10 reduction in viral loads. 66, 139, 142 As discussed above, model analysis of viral kinetic models revealed that this is because the processes that the drugs target (ie, the viral life cycle) dominate only in the early stages of infection. 65 Reduced efficacy and less than 1 log 10 lower viral load are achieved if the drug is given in latter stages of infection (>3 days pi) 143 when viral load kinetics are influenced predominantly by clearance mechanisms (eg, infected cell clearance (δ) and, to a lesser extent, virus clearance (c)). 65 Estimates of antiviral efficacy can be obtained from simulating the model and altering the rate of virus production,
V is the efficacy of the antiviral. 14 Drug effectiveness is equal to 1 when the drug is 100% effective and 0 when the drug is inactive or absent. Model simulations suggest that targeting virus infection (β) would yield similar results as targeting virus production and that increased efficacy would be needed for an antiviral that improves clearance of free virus (c). 36 Unsurprisingly, a therapy designed to improve the timing and/or rate of infected cell clearance (δ) could result in faster resolution. 36 
| Detecting off target immune effects
A secondary effect of NAI therapy was detected in one study that assessed viral load kinetics when therapy was initiated either early or late in the infection. 36 An extra term (− T T) in the target cell equation together with the reduction in the rate of virus production (p(1 − v )) was needed in the model to simultaneously capture the data 36 : dT∕dt = − TV − T T, where T is the efficacy of the antiviral in reducing the number of cells susceptible to infection. The requirement of the − T T term in the model suggests that the antiviral limits the number of cells that can be infected. Indeed, this was independently observed in an experiment that assessed the area of the lung infected during therapy. 54 Neither the model nor the viral load data identify the underlying mechanism. Interestingly, the predicted efficiency of this off-target effect was significantly greater than the predicted efficacy of the antiviral inhibiting virus production (70% vs 10%). 36 The lack of reduced viral loads even when fewer cells are in- Nevertheless, the reduced lung involvement would undoubtedly reduce symptoms, improve wound healing capabilities, and reduce subsequent comorbidities (eg, bacteria superinfection (discussed further below)).
| Potential adverse consequences of antiviral therapy during virus coinfection
Although antivirals exist for treatment of influenza virus infection, antivirals targeting other coinfecting viruses (eg, RV, RSV, and PIV) have not been approved for use or are currently in development. 144 Given that different virus pairings result in different outcomes (ie, infection enhancement or reduction), use of anti-influenza therapy could result in beneficial or adverse consequences. 42 In the case of IAV-RSV coinfection, where influenza viruses reduce RSV growth, 104, 106 (discussed further below). 143 Predicting outcomes from each of these scenarios are needed and ideal for investigation with mathematical models.
| A role for antivirals and combination therapy in limiting bacterial coinfection
Because antivirals restrict viral growth and influenza disease severity, morbidity and mortality from invading bacterial pathogens can also be reduced. 143 However, the time-dependent efficacies observed during IAV infection are also reflected during bacterial coinfection, where NAI prophylaxis is more potent in reducing coinfection-related a is the efficacy of the therapy). 36 As expected, bacterial burden and pneumonia were reduced. 113 Although antibiotics have diminished efficacy during coinfection, 145 analytical results suggest that combination therapy could increase the chances of successful immunotherapy or antiviral treatment by over 200%. 36 This is because changes in the bacterial growth rate (r) also facilitates different outcomes of influenza-bacterial coinfection. 36 Similar to the degree of aMΦ depletion (̂(V)), the bacterial growth rate (r) is a bifurcation parameter and, thus, a drug target (eg, with protein synthesis inhibitors). 36 However, the efficacy needed to sufficiently reduce bacteria through this class of drugs may be higher than immunomodulatory drugs. 36 
| CON CLUD ING REMARK S AND PER S PEC TIVE S
Influenza viruses continue to infect millions each year. Increased severity and case fatality rates due to secondary bacterial pneumonia have been emphasized by studies of the 1918, 1957, 1968, and 2009 influenza pandemics. 107, 109, 110, 146 Influenza viruses that cause severe disease support higher incidence of bacterial coinfection, yet only a proportion of infections result in a coinfection. [94] [95] [96] Furthermore, other respiratory viruses may also coinfect and enhance influenzarelated disease. 103, 105, 106 Factors that impact influenza severity and, thus, coinfection risk are not well understood. Given that numerous viruses and bacteria can enhance influenza virulence and that two or more pathogens are often detected in individuals with pneumonia, understanding how different pathogens synergize is critical.
Potentially even more important is discovering how antecedent viral or bacterial infections decrease influenza spread because the underlying mechanism(s) could be leveraged as drug therapy. However, knowledge about host immune control during influenza remains nological advances continue to improve data quality and quantity and more data on viral-bacterial and viral-viral coinfections materializes, mathematical analyses like those described here will be critical.
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